A new method for detecting liver cancer
Release date: 2007-08-13
A new method for detecting liver cancer Liver cancer is a very difficult cancer to diagnose, and this cancer is also an important cause of death in Asia and Africa. Moreover, the incidence of liver cancer in recent years has also increased year by year in Western countries. Now, researchers at VIB University's VIB have collaborated with research centers in Beijing and Shanghai to open a way to detect liver cancer at an early stage. This method of detection requires only a small blood sample. This new assay method accurately detects more than 50% of cases that were previously undetectable.
Hepatocellular carcinoma (HCC) is the most common type of liver cancer. Chronic inflammation caused by hepatitis B, hepatitis C virus infection or cirrhosis often leads to the occurrence of liver cancer. Cirrhosis is a general term for a group of liver diseases characterized by destruction of liver cells and replacement by scar tissue. This condition reduces the amount of healthy liver tissue and the accumulation of scar tissue interferes with the development and function of liver tissue. There are many different causes of cirrhosis, including excessive drinking, chronic viral hepatitis B, hepatitis C and hepatitis D infection, bile duct disease, and parasitic infections.
In China, about 500,000 patients die each year from cirrhosis or liver cancer, and 60% to 80% of liver cancer patients have a history of cirrhosis. In Belgium, there are 350 new cases of liver cancer each year. For liver cancer patients, transplantation is often the only hope. The ability to detect and diagnose HCC at an early stage will likely save countless lives.
Some current methods for detecting tumor growth often rely on the concentration of specific markers present in the blood. For the detection of HCC, usually only one marker AFP is used. The specificity of this marker is low and often results in false positives.
Xue-en Liu (transliteration), Liesbeth Desmyter and colleagues invented this new method for detecting stem cell cancer under the guidance of Cuiying Chen. This test was developed on the basis of previous work by Professor Roland Contreras and Nico Callewaert.
By analyzing the blood of Chinese patients with cirrhosis caused by hepatitis B virus infection, they found that the two specific sugar groups on the blood protein vary depending on the stage of development of the disease. Moreover, these values ​​are related to the size of the tumor. The ratio of these data forms the basis of this new blood test method. The rate at which researchers make a correct diagnosis is 70% - this success rate is essentially the same as the AFP tumor marker method currently in use.
The researchers said that if the AFP assay is used in conjunction with this new method, the diagnostic accuracy of hepatocellular carcinoma will be greatly improved. This new method can diagnose half of the cases of cirrhosis patients who cannot make judgments using the AFP method. This assay will enable doctors to perform higher-frequency, non-invasive analysis of patients with cirrhosis and enable researchers to detect liver cancer at an early stage and to closely monitor the development of the disease.
Currently, researchers are testing the diagnostic effects of this approach in clinical practice in the century. The new structure for the diagnosis of stem cell cancer provides new impetus for a close study of the pathogenesis of this disease.
Liver cancer is one of the common malignant tumors in China. It is the second-most cancer killer in China and is common in middle-aged men. Because of its high degree of malignancy and rapid progression of the disease, there is usually no discomfort in the early stage of the patient. Once symptoms appear, it is often in the middle and late stages. Therefore, the treatment is difficult and the curative effect is poor. The general survival time after the onset is only 6 months, and it is called "the king of cancer".
The symptoms of liver cancer are not obvious at an early stage, and even patients have no feeling after a long time after illness. When the disease develops to a certain extent, some symptoms of liver pain, loss of appetite, fatigue, fatigue, and weight loss will gradually occur. There will be jaundice, ascites, hematemesis, coma and other performances. The upper abdomen of liver cancer patients can often touch a huge mass, but at this time it has reached the middle and late stage, and even has been transferred to the lungs. The total course of liver cancer is about two and a half years, two of which are in the early stages of no symptoms, and once the symptoms appear, there is only half a year of survival. —Midi Medical Network
Plasma Products,Anti-Hbs,Safe Plasma,Safe Plasma Storage
Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. , https://www.syimmunoglobulin.com